Literature DB >> 29980629

Natural history of mitochondrial disorders: a systematic review.

Nandaki Keshavan1, Shamima Rahman2,3.   

Abstract

The natural history of a disease defines the age of onset, presenting features, clinical phenotype, morbidity and mortality outcomes of disease that is unmodified by treatments. A clear understanding of the natural history of mitochondrial disorders is essential for establishing genotype-phenotype-prognosis correlations. We performed a systematic review of the reported natural history of mitochondrial disease by searching the literature for all published natural history studies containing at least 20 individuals. We defined a phenotype as 'common' if it was observed in ≥30% of cases in a study, thereby highlighting common and uncommon phenotypes for each disorder. Thirty-seven natural history studies were identified encompassing 29 mitochondrial disease entities. Fifty-nine percent of disorders had an onset before 18 months and 81% before 18 years. Most disorders had multisystemic involvement and most often affected were the central nervous system, eyes, gastrointestinal system, skeletal muscle, auditory system and the heart. Less frequent involvement was seen for respiratory, renal, endocrine, hepatic, haematological and genitourinary systems. Elevated lactate was the most frequent biochemical abnormality, seen in 72% of disorders. Age of death was <1 y in 13% of disorders, <5 y in 57% and <10 y in 74%. Disorders with high mortality rates were generally associated with earlier deaths. The most robust indicators of poor prognosis were early presentation of disease and truncating mutations. A thorough knowledge of natural history has helped to redefine diagnostic criteria for classical clinical syndromes and to establish a clinical baseline for comparison in single-arm clinical trials of novel therapies.
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  Mitochondrial disease; Natural history; Outcomes; Phenotype; Survival

Mesh:

Year:  2018        PMID: 29980629     DOI: 10.1042/EBC20170108

Source DB:  PubMed          Journal:  Essays Biochem        ISSN: 0071-1365            Impact factor:   8.000


  8 in total

1.  Outcome measures for children with mitochondrial disease: consensus recommendations for future studies from a Delphi-based international workshop.

Authors:  Saskia Koene; Lara van Bon; Enrico Bertini; Cecilia Jimenez-Moreno; Lianne van der Giessen; Imelda de Groot; Robert McFarland; Sumit Parikh; Shamima Rahman; Michelle Wood; Jiri Zeman; Anjo Janssen; Jan Smeitink
Journal:  J Inherit Metab Dis       Date:  2018-07-19       Impact factor: 4.982

2.  Blended cognitive behaviour therapy for children and adolescents with mitochondrial disease targeting fatigue (PowerMe): study protocol for a multiple baseline single case experiment.

Authors:  I L Klein; K F E van de Loo; T J Hoogeboom; M C H Janssen; J A M Smeitink; E van der Veer; C M Verhaak; J A E Custers
Journal:  Trials       Date:  2021-03-01       Impact factor: 2.279

3.  Clinical and molecular characterization of mitochondrial DNA disorders in a group of Argentinian pediatric patients.

Authors:  Mariana Amina Loos; Gimena Gomez; Lía Mayorga; Roberto Horacio Caraballo; Hernán Diego Eiroa; María Gabriela Obregon; Carlos Rugilo; Fabiana Lubieniecki; Ana Lía Taratuto; María Saccoliti; Cristina Noemi Alonso; Hilda Verónica Aráoz
Journal:  Mol Genet Metab Rep       Date:  2021-02-25

4.  Community Consensus Guidelines to Support FAIR Data Standards in Clinical Research Studies in Primary Mitochondrial Disease.

Authors:  Amel Karaa; Laura E MacMullen; John C Campbell; John Christodoulou; Bruce H Cohen; Thomas Klopstock; Yasutoshi Koga; Costanza Lamperti; Rob van Maanen; Robert McFarland; Sumit Parikh; Shamima Rahman; Fernando Scaglia; Alexander V Sherman; Philip Yeske; Marni J Falk
Journal:  Adv Genet (Hoboken)       Date:  2021-12-19

5.  Decrease of MtDNA copy number affects mitochondrial function and involves in the pathological consequences of ischaemic stroke.

Authors:  Zhaojing Zhang; Dongzhi Yang; Baixue Zhou; Yingying Luan; Qihui Yao; Yang Liu; Shangdong Yang; Jing Jia; Yan Xu; Xiaoshuai Bie; Yuanli Wang; Zhihao Li; Aifan Li; Hong Zheng; Ying He
Journal:  J Cell Mol Med       Date:  2022-07-05       Impact factor: 5.295

Review 6.  Towards a therapy for mitochondrial disease: an update.

Authors:  Caterina Garone; Carlo Viscomi
Journal:  Biochem Soc Trans       Date:  2018-10-08       Impact factor: 5.407

Review 7.  Towards Central Nervous System Involvement in Adults with Hereditary Myopathies.

Authors:  Jens Reimann; Cornelia Kornblum
Journal:  J Neuromuscul Dis       Date:  2020

Review 8.  Moving towards clinical trials for mitochondrial diseases.

Authors:  Robert D S Pitceathly; Nandaki Keshavan; Joyeeta Rahman; Shamima Rahman
Journal:  J Inherit Metab Dis       Date:  2020-09-02       Impact factor: 4.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.